{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:43:03Z","timestamp":1793295783243,"version":"4.5.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204758"],"award-info":[{"award-number":["82204758"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used due to their profound efficacy in glycemic control and weight management. Within real-world contexts, the manifestation of certain psychiatric adverse events (AEs) has been observed, which is potentially linked to the administration of GLP-1 RAs. The objective of this study was to undertake a comprehensive investigation and characterization of the psychiatric AEs associated with GLP-1 RAs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrieved reports of AEs associated with treatment with GLP-1 RAs during the period from the first quarter (Q1) of 2004 to Q1 2023 from the FDA Adverse Event Reporting System (FAERS) database. Descriptive analysis was performed to examine the clinical characteristics and time to onset of the psychiatric AEs caused by GLP-1 RAs. Moreover, disproportionality analyses were performed using the reporting odds ratio (ROR) to identify GLP-1 RA-related psychiatric AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 8,240 reports of psychiatric AEs were analyzed out of 181,238 AE reports with treatment with GLP-1 RAs. Among these cases, a higher percentage was represented by women compared to men (65.89%\n                      <jats:italic>vs<\/jats:italic>\n                      . 30.96%). The median age of these patients was 56 years, with an interquartile range (IQR) of 48\u201367 years, based on data available in 286 case reports. This study showed that the median time to onset of the overall GLP-1 RA-related AEs was 31 days (IQR = 7\u2013145.4 days), which varied among GLP-1 RA regimens. Specifically, exenatide had a significantly longer onset time at 45 days (IQR = 11\u2013213 days), with statistically significant differences from the onset times of the other five GLP-1 RAs (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.0001). Moreover, eight categories of psychiatric AEs, namely, nervousness (ROR = 1.97, 95% CI = 1.85\u20132.11), stress (ROR = 1.28, 95% CI = 1.19\u20131.38), eating disorder (ROR = 1.57, 95% CI = 1.40\u20131.77), fear of injection (ROR = 1.96, 95% CI = 1.60\u20132.40), sleep disorder due to general medical condition\u2014insomnia type (ROR = 2.01, 95% CI = 1.60\u20132.52), binge eating (ROR = 2.70, 95% CI = 1.75\u20134.16), fear of eating (ROR 3.35, 95% CI = 1.65\u20136.78), and self-induced vomiting (ROR = 3.77, 95% CI = 1.77\u20138.03), were defined as GLP-1 RA-related psychiatric AEs through disproportionality analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings demonstrate a significant association between GLP-1 RAs and the development of specific psychiatric AEs. Despite the observational nature of this pharmacovigilance study and the inherent limitations of the FAERS database, our preliminary findings in this work could provide a better basis for understanding the potential psychiatric AEs that may occur with GLP-1 RA treatment, assisting clinicians to focus on these AEs and provide early intervention for optimal risk management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2024.1330936","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T07:31:37Z","timestamp":1707377497000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":76,"title":["Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database"],"prefix":"10.3389","volume":"15","author":[{"given":"Wei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peishan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","year":"2023","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97233","article-title":"Discovery, characterization, and clinical development of the glucagon-like peptides","volume":"127","author":"Drucker","year":"2017","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/dom.13162","article-title":"A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials","author":"Aroda","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/00207454.2021.1924707","article-title":"The pleiotropic of GLP-1\/GLP-1R axis in central nervous system diseases","volume":"133","author":"Zhang","year":"2023","journal-title":"Int J Neurosci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e13435","DOI":"10.1111\/obr.13435","article-title":"Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials","volume":"23","author":"Iqbal","year":"2022","journal-title":"Obes Rev"},{"key":"B8","unstructured":"Financial results of Novo Nordisk"},{"key":"B9","unstructured":"European medicines agency"},{"key":"B10","doi-asserted-by":"publisher","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: A systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.psyneuen.2015.11.021","article-title":"GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality","volume":"65","author":"Anderberg","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.925377","article-title":"GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2021.10.003","article-title":"The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system","volume":"32","author":"Yang","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21694","article-title":"Thyroid dysfunction associated with iodine-contrast media: A real-world pharmacovigilance study based on the FDA adverse event reporting system","volume":"9","author":"Huang","year":"2023","journal-title":"Heliyon"},{"key":"B17","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1937","article-title":"Exenatide-induced depression in a geriatric patient","volume":"23","author":"Kohen","year":"2008","journal-title":"Int J Geriatr Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2017.08.433","article-title":"Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders","volume":"27","author":"Mansur","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s13311-017-0585-0","article-title":"Anxiety, depression, and the microbiome: A role for gut peptides","volume":"15","author":"Lach","year":"2018","journal-title":"Neurotherapeutics"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2018.11.001","article-title":"Hypothalamic insulin and glucagon-like peptide-1 levels in an animal model of depression and their effect on corticotropin-releasing hormone promoter gene activity in a hypothalamic cell line","volume":"71","author":"Detka","year":"2019","journal-title":"Pharmacol Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13574","article-title":"Clinical review of subcutaneous semaglutide for obesity","volume":"47","author":"Phillips","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24539","article-title":"FDA green-lights tirzepatide, marketed as zepbound, for chronic weight management","volume":"330","author":"Abbasi","year":"2023","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.12758\/mda.2021.08","article-title":"Gender and survey participation.An event history analysis of the gender effects of survey participation in a probability-based multi-wave panel study with a sequential mixed-mode design","volume":"16","author":"Becker","year":"2022","journal-title":"Methods Data Analyses"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e3070","DOI":"10.1002\/dmrr.3070","article-title":"Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same","volume":"35","author":"Gentilella","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2006.01943.x","article-title":"The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis","volume":"23","author":"Ali","year":"2006","journal-title":"Diabetes Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05609-x","article-title":"Prevalence of type 2 diabetes in psychiatric disorders: an umbrella review with meta-analysis of 245 observational studies from 32 systematic reviews","volume":"65","author":"Lindekilde","year":"2022","journal-title":"Diabetologia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1995","article-title":"Longitudinal association of depressive symptoms, binge eating, and quality of life with cardiovascular risk factors in young adults with youth-onset type 2 diabetes: the TODAY2 study","volume":"45","author":"Group","year":"2022","journal-title":"Diabetes Care"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2023.05.041","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review","volume":"164","author":"Cooper","year":"2023","journal-title":"J Psychiatr Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2020.03.009","article-title":"Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study","volume":"14","author":"Da Porto","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"B35","doi-asserted-by":"publisher","first-page":"113967","DOI":"10.1016\/j.physbeh.2022.113967","article-title":"Short term effects of semaglutide on emotional eating and other abnormal eating patterns among subjects living with obesity","volume":"257","author":"Nicolau","year":"2022","journal-title":"Physiol Behav"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1330936\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T07:31:43Z","timestamp":1707377503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1330936\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":35,"alternative-id":["10.3389\/fendo.2024.1330936"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1330936","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"article-number":"1330936"}}